Eli Lilly's Inluriyo-Verzenio Combo Gets Full FDA Approval for Breast Cancer

Eli Lilly (LLY) has received full FDA approval for its Inluriyo (imlunestrant) and Verzenio (abemaciclib) combination therapy for ESR1-mutated, ER-positive, HER2-negative metastatic breast cancer 🔗.

Key details:

• Approved for patients whose disease progressed after at least one line of endocrine therapy.
• Based on Phase 3 EMBER-3 trial, the combo doubled median progression-free survival to 11.1 months vs. 5.5 months for Inluriyo alone (HR 0.53).
• This marks Inluriyo's second FDA approval in less than a year, expanding its market potential.
• The combination targets two drivers of tumor growth, offering a new treatment option.